Zhao and coworkers have characterized the molecular properties of HER2-positive breast cancers subdivided according to the expression of ER and PR, with particular emphasis on the triple-positive (ER+PR+HER2+) subgroup [82]. This evidence concerns the gene ESR1 and breast cancer.